China SXT Pharmaceuticals, Inc.
SXTC · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $2 | $2 | $2 | $3 |
| % Growth | -9.7% | -2.2% | -24.2% | – |
| Cost of Goods Sold | $1 | $1 | $2 | $1 |
| Gross Profit | $0 | $1 | $0 | $1 |
| % Margin | 21.1% | 28.7% | 21.6% | 48.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $3 | $3 | $6 | $6 |
| SG&A Expenses | $3 | $3 | $6 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $1 |
| Other Operating Expenses | -$0 | -$0 | $0 | $0 |
| Operating Expenses | $3 | $3 | $6 | $6 |
| Operating Income | -$3 | -$3 | -$6 | -$5 |
| % Margin | -154% | -130.4% | -284.4% | -199.4% |
| Other Income/Exp. Net | -$1 | -$1 | -$0 | -$0 |
| Pre-Tax Income | -$3 | -$3 | -$6 | -$5 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3 | -$3 | -$6 | -$6 |
| % Margin | -189.8% | -160.7% | -301% | -220.4% |
| EPS | -8.18 | -3.57 | -22.23 | -137.92 |
| % Growth | -129.1% | 83.9% | 83.9% | – |
| EPS Diluted | -8.18 | -3.57 | -22.23 | -137.92 |
| Weighted Avg Shares Out | 0 | 1 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 1 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3 | -$2 | -$5 | -$5 |
| % Margin | -147.8% | -121.9% | -264.1% | -194.1% |